Prelude Therapeutics Files 2024 Annual Report

Ticker: PRLD · Form: 10-K · Filed: Mar 10, 2025 · CIK: 1678660

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Prelude Therapeutics dropped its 2024 10-K on March 10th. Check financials and strategy.

AI Summary

Prelude Therapeutics Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 10, 2025. The company, operating in the Pharmaceutical Preparations sector, is incorporated in Delaware and headquartered in Wilmington, DE. Key financial data and operational details for the period are presented in this comprehensive annual report.

Why It Matters

This filing provides investors and stakeholders with a detailed overview of Prelude Therapeutics' financial health, operational performance, and strategic direction for the past fiscal year.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Prelude Therapeutics is subject to significant risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is Prelude Therapeutics Inc.'s primary business activity?

Prelude Therapeutics Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code 2834.

When did Prelude Therapeutics Inc. file its 10-K report?

Prelude Therapeutics Inc. filed its 10-K report on March 10, 2025.

For which fiscal year is this 10-K report filed?

This 10-K report is filed for the fiscal year ending December 31, 2024.

Where is Prelude Therapeutics Inc. headquartered?

Prelude Therapeutics Inc. is headquartered in Wilmington, DE.

What is the SEC file number for Prelude Therapeutics Inc.'s 10-K filing?

The SEC file number for Prelude Therapeutics Inc.'s 10-K filing is 001-39527.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 10, 2025 regarding Prelude Therapeutics Inc (PRLD).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing